Company intelligence / Profile preview
M Bio Technology Inc.
- Ownership
- Private
- Development stage
- Other
Overview
M Bio Technology has developed proprietary diagnostic platforms and is advancing first-in-class chemically synthesized glycolipid-antigen vaccines targeting mycoplasma-related diseases. Their ELISA-based diagnostics are already being used clinically in Japan. They are pursuing clinical trial programs for vaccine candidates addressing neurological autoimmune conditions like CIDP and GBS, as well as exploring applications for post-COVID syndromes. No published late-stage clinical results yet.
- Therapeutic areas
- PulmonologyImmunologyRheumatologyNeurologyNephrologyInfectious Diseases
- Modalities
- Vaccines (chemically synthesized glycolipid-antigen vaccines)Monoclonal antibodiesDiagnostic assays (ELISA, MID Prism®)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on M Bio Technology Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M Bio Technology Inc..